PMV Pharmaceuticals Inc. – Material Contracts Watch

from 10-K 8 pages PMV Pharmaceuticals, Inc. Clinical Advisory Board Consulting Agreement

from 10-K 4 pages PMV Pharmaceuticals, Inc. Outside Director Compensation Policy

from 10-Q 3 pages Change in Control and Severance Policy (The "Policy") Amended and Restated Participation Agreement

from 10-Q 4 pages November 5, 2024 Robert Ticktin C/O PMV Pharmaceuticals

from 10-Q 4 pages PMV Pharmaceuticals, Inc. Outside Director Compensation Policy

from 8-K 7 pages Lease Termination Agreement

from 10-Q 22 pages Purpose. the Purpose of the Plan Is to Provide Employees of the Company and Its Designated Companies With an Opportunity to Purchase Common Stock Through Accumulated Contributions. the Company Intends for the Plan to Have Two Components: A Component That Is Intended to Qualify as an “Employee Stock Purchase Plan” Under Section 423 of the Code (The “423 Component”) and a Component That Is Not Intended to Qualify as an “Employee Stock Purchase Plan” Under Section 423 of the Code (The “Non-423 Component”). the Provisions of the 423 Component, Accordingly, Will Be Construed So as to Extend and Limit Plan Participation in a Uniform and Nondiscriminatory Basis Consistent With the Requirements of Section 423 of the Code. an Option to Purchase Shares of Common Stock Under the Non-423 Component Will Be Granted Pursuant to Rules, Procedures, or Sub-Plans Adopted by the Administrator Designed to Achieve Tax, Securities Laws, or Other Objectives for Eligible Employees and the Company. Except as Otherwise Provided Herein or by the Administrator, the Non-423 Component Will Operate and Be Administered in the Same Manner as the 423 Component. 2. Definitions. (A) “Administrator” Means the Board or Any Committee Designated by the Board to Administer the Plan Pursuant to Section 14. (B) “Affiliate” Means Any Entity, Other Than a Subsidiary, in Which the Company Has an Equity or Other Ownership Interest

from 10-K 4 pages Change in Control and Severance Policy (The "Policy") Amended and Restated Participation Agreement

from 10-K Pdf Courtesy Copy

from 10-K 9 pages PMV Pharmaceuticals, Inc. Consulting Agreement

from 10-K 4 pages January 05, 2024 Michael Carulli C/O PMV Pharmaceuticals, Inc. Dear Mike,

from 10-K 4 pages January 05, 2024 via Email Dear Leila, This Letter Memorializes the Terms and Conditions for Your Separation From Employment as the Chief Medical Officer for PMV Pharma (The "Company"), Effective as of the Date Hereof (“Separation Date”). 1. Consideration. in Consideration of Your Execution of This Letter and Your Fulfillment of All of Its Terms and Conditions, Company Shall Make the Following Consideration Payments to You: A

from 10-K 10 pages PMV Pharmaceuticals, Inc. Consulting Agreement

from 10-K 5 pages PMV Pharmaceuticals, Inc. Outside Director Compensation Policy

from 10-K 5 pages PMV Pharmaceuticals, Inc. Outside Director Compensation Policy 1. Cash Compensation Annual Cash Retainer Each Outside Director Will Be Paid an Annual Cash Retainer of $40,000. There Are No Per-Meeting Attendance Fees for Attending Board Meetings. This Cash Compensation Will Be Paid Quarterly in Arrears on a Prorated Basis. Committee Annual Cash Retainer

from 10-Q 4 pages Reviewed & Updated by PMV Board as Of: May 05, 2022 (“Updated Effective Date”) PMV Pharmaceuticals, Inc. Outside Director Compensation Policy 1. Cash Compensation Annual Cash Retainer Each Outside Director Will Be Paid an Annual Cash Retainer of $40,000. There Are No Per-Meeting Attendance Fees for Attending Board Meetings. This Cash Compensation Will Be Paid Quarterly in Arrears on a Prorated Basis. Committee Annual Cash Retainer

from 10-Q 3 pages Change in Control and Severance Policy Amended and Restated Participation Agreement

from 10-K 9 pages PMV Pharmaceuticals, Inc. Amended & Restated Sab Consulting Agreement

from 10-K 3 pages Change in Control and Severance Policy Amended and Restated Participation Agreement This Amended and Restated Participation Agreement ("Agreement") Is Made and Entered Into by and Between Deepika Jalota on the One Hand, and PMV Pharmaceuticals, Inc. (The "Company") on the Other. • Equity Vesting: 100% of the Then-Unvested Shares Subject to Each of Your

from 10-K 3 pages Material contract